Coeptis Therapeutics Inc. (NASDAQ: COEP), a pre-clinical stage biopharmaceutical Corp, announced an exclusive term sheet (expires 31 Aug 23) to acquire or license Deverra Therapeutics’ platform asset onto which COEP’s SNAP-CAR and GEAR platforms could ‘dovetail’ and create a potentially very broad application set of immune technologies. Deverra’s proprietary allogeneic stem cell platform side steps patient donor matching to produce a broad range of immune effector cells, which can kill cancer an ....
